Insulin degludec is a long-acting insulin analog.It is a synthetic form of human insulin.It is produced using recombinant DNA technology.Insulin degludec is available as a clear, colorless solution in vials or prefilled pens.
Management of type 1 diabetes mellitus in adults, adolescents, and children 2 years of age and older.
Management of type 2 diabetes mellitus in adults when diet and exercise are not enough to control blood sugar.
Tresiba 100iu Penfill Inj 3ml (Insulin Degludec) lowers blood sugar levels by stimulating the uptake of glucose by cells, inhibiting the production of glucose by the liver, and reducing the breakdown of fat.
Store unopened vials and pens in a refrigerator at 2°C to 8°C (36°F to 46°F).
Do not freeze.
Protect from light.
Once opened, vials can be stored at room temperature (up to 25°C/77°F) for up to 28 days.
Opened pens can be stored at room temperature (up to 25°C/77°F) for up to 28 days.
Do not use insulin degludec after the expiration date printed on the vial or pen.
Dispose of used needles safely.
Keep insulin degludec out of reach of children and pets.
The dosage of insulin degludec is individualized and depends on the patient's needs.
It is typically administered once daily by subcutaneous injection.
Injection sites should be rotated.
Do not inject into veins or arteries.
Do not mix insulin degludec with other insulin products or solutions.
Consult your healthcare provider for specific dosage instructions.
Hypoglycemia (low blood sugar)
Injection site reactions (redness, swelling, itching)
Allergic reactions (rash, hives, difficulty breathing)
Weight gain
Fluid retention
Vision changes
Alcohol can affect blood sugar levels and may interact with insulin degludec. Consult your healthcare provider about the safe consumption of alcohol while taking insulin degludec.
Hypoglycemia can cause dizziness, impaired concentration, and drowsiness. Avoid driving or operating machinery if you experience hypoglycemia.
Insulin degludec is generally considered safe for use during pregnancy and breastfeeding. However, consult your healthcare provider about the risks and benefits.
Insulin degludec is safe and effective for children 2 years of age and older.
Kidney disease may affect the dosage and monitoring of insulin degludec.
Liver disease may affect the dosage and monitoring of insulin degludec.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-hypoglycemia-risk-with-certain-diabetes-medicines
https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-causes/syc-20351193
https://www.diabetes.org/diabetes-basics/diabetes-care/insulin-therapy/types-of-insulin
